A new item has been added to the shopping cart


Tell to a friend

Your Name:
E-mail of your friend:
Captcha CAPTCHA code
Enter the text in the image above


Already a subscriber? Log in now for online Access.


Artículo Tomo 71, Número. 3, Abril 2018

Archivos Españoles de Urología

The role of chemotherapy in the treatment of hormone sensitive metastatic prostate cancer.

Authors: José Luis Pérez-Gracia, Fernando Diez Caballero, Alfonso Gúrpide, Fernando Ramón de Fata Chillón y Felipe Villacampa.

Arch. Esp. Urol. 2018; 71 (3): 276-280

Vol. 71, Number. 3, April 2018

OBJECTIVE: Several studies have assessed the role of adding chemotherapy to hormonal treatment for metastatic hormone-sensitive prostate cancer (MHSPC). The objective of this manuscript is to review these studies and to provide recommendations for the management of these patients.

METHODS: We identified published clinical trials comparing hormone blockade (HB) with HB plus docetaxel as first-line treatment of HSMPC and we analyzed their results in terms of efficacy and toxicity.

RESULTS: Of the 3 trials published, two demonstrated increased overall survival by adding docetaxel to the first-line treatment of MHSPC (CHAARTED and Stampede-Docetaxel studies) and the third one did not show such an advantage (GETUG-AFU15). In the CHAARTED study, the survival advantage was limited to patients presenting high tumor volume. Toxicity was increased in patients who received docetaxel.

CONCLUSIONS: The addition of docetaxel to treatment with HB should be considered in patients with MHSPC, especially in those with high tumor volume. However, the toxicity and recent results of trials performed with abiraterone in MHSPC should also be taken in consideration.


Only subscribers

Copyright © 2015 | Valid support N°12/08-W-CM | ISSN-ONLINE: 1576-8260 |